China’s National Medical Products Administration has signed off on a clinical trial evaluating a COVID-19 vaccine made with proteins grown in insect cells, an approach that could speed up large-scale production.
The trial will be conducted by the West China Hospital of Sichuan University in Chengdu.
The vaccine prevented infection with no obvious side effects in a non-human primate study.
Chinese authorities also announced that they have been testing a potential coronavirus vaccine in a select group of workers, primarily border officials and health workers, since July, the first confirmation by any country of such activity outside of clinical trials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.